Skip to content
City AM
Main navigation
Download free app
  • News
    • News
      • Latest Business News
      • Economics
      • Politics
      • Insurance
      • Square Mile and me
      • Tech
      • Legal
      • Banking
      • Property
      • Retail
      • Crypto
      • Transport
    • From our partners
      • AON
      • Tottenham Hotspur Stadium
      • Eastern City BID
      • London Stansted Airport
      • YourCause from Blackbaud
      • Inside Saudi
      • Central London Alliance CIC
    • Featured

      test

      Submit a story

      Tell us your story.

      Submit
  • Opinion
  • Sport
    • Latest Sports News
      • Sport
      • Sport Business
      • The Punter
    • From our partners
      • The Morning Briefing: SBS x City AM
      • Aramco Team Series
      • LIV Golf
    • Featured

      Premiership run-in: Saints and Bath will impact top four

      2Look at the Premiership table and you’ll see that the top team and Challenge Cup finalists Bath are 15 points clear of second-placed Leicester Tigers, and Champions Cup finalists Northampton Saints are 17 points safe from dropping out of the top eight.

      Submit a story

      Tell us your story.

      Submit
  • Investec
  • Life&Style
    • Life&Style
      • Life&Style
      • The Magazine
      • Travel
      • Culture
      • Motoring
      • Wellness
      • The RED BULLETiN
      • Do it with Shared Ownership
      • The King’s Awards 2024
    • Featured

      Here We Are, National Theatre, review: Stephen Sondheim musical is more Severance than sing-a-long

      Rory Kinnear and Jane Krakowski lead the cast in Here We Are, the final show with music from the composer Stephen Sondheim (Photo: Marc Brenner)

      Submit a story

      Tell us your story.

      Submit
  • Latest Paper
  • Personal Finance
  • CityAM Awards
  • Sign In
  • Sign Out
  • My Account

Don’t invest unless you’re prepared to lose all the money you invest. This is a high-risk investment and you should not expect to be protected if something goes wrong.

Take 2 mins to learn more at www.coinbase.com/uk-fca-info

FDA

  • GSK wins latest Zantac trial as jury finds drug did not cause woman’s cancer

    pharma

    GSK - formerly GlaxoSmithKline - has won its latest trial over whether its most popular drug caused cancer on Monday, after a jury found it was not the root cause of an American woman's illness.

    GSK said on Monday its blood cancer drug Blenrep, when used as a second-line treatment in patients with myeloma, met its primary goal.
  • GSK: Good news for pharma giant as approval granted to expand vaccine use

    BUSINESS

    The FDA has expanded its approval of a GSK vaccine that prevents respiratory syncytial virus (RSV) to affect younger adults, in a move the company hopes will prevent thousands of hospitalisations each year.

    The FDA has expanded its approval of a GSK vaccine that prevents respiratory syncytial virus (RSV) to include younger adults, in a move the company hopes will prevent thousands of hospitalisations each year.
  • Investors in London-listed medical tech firm continue battle to oust top brass

    BUSINESS

    Investors in a London-listed medical technology firm are continuing their campaign to oust the company’s top brass as its share price languishes. 

    Hedge fund Saba Capital owns a significant stake in all seven trusts.
  • US regulator accepts GSK’s application to expand treatment of cancer drug

    April 24, 2024

    The treatment, Jemperli, will now be classed as being able to help all adult patients with primary advanced or recurrent endometrial cancer. It is used alongside chemotherapy.

Trending Articles

  • Verdane-Backed Corlytics Is a Category Leader in the Chartis RiskTech Quadrant for Regulatory Intelligence

  • ‘I’ve directed Sir David Attenborough for 40 years – these are my best stories’

  • Partnership crisis: Gen Z doesn’t want to follow the traditional legal career pathway

  • JCB billionaire and Brexit champion Lord Bamford retires from House of Lords

  • Kairos by Jenny Erpenbeck: Review

  • test_editor

  • Profit at Lloyd’s of London surges thanks to higher interest rates and premiums

  • Football’s MCO rules ‘beneficial’ to likes of Manchester City and ‘need change’

  • Verdane-Backed Corlytics Is a Category Leader in the Chartis RiskTech Quadrant for Regulatory Intelligence

  • Ares Management to Acquire BlueCove

Subscribe

Subscribe to the City AM newsletter to have our top stories delivered directly to your inbox.

Subscribe
  • About us
  • Careers
  • Terms & Conditions
  • Privacy Policy
  • Cookie Policy
  • News
  • Markets & Economics
  • Opinion
  • Life&Style
  • Personal Finance
  • Got a story?
  • The Punter
  • City AM Curated
  • Wine
  • Casino

Follow us for breaking news and latest updates

  • Facebook
  • X
  • Instagram
  • LinkedIn
  • Newsletters
  • Advertising
  • About
  • Tickets
Copyright 2025 City AM Limited